The North America real world evidence solutions market size was estimated at USD 1.34 billion in 2025 and is projected to reach USD 2.52 billion by 2033, growing at a CAGR of 8.29% from 2026 to 2033. Market growth is driven by the increasing use of real-world data in regulatory decision-making, the rising demand for value-based healthcare, and the need among pharmaceutical and biotechnology companies to generate post-market evidence on drug safety and effectiveness.
The North America Real-World Evidence (RWE) solutions industry is growing, driven by strong regulatory support for the adoption of RWE solutions and expanding investments in biomedical and translational research. For instance, according to the National Center for Science and Engineering Statistics, in 2024, R&D expenditures in health sciences reached USD 38.5 billion, up USD 2.8 billion from 2023, while biological and biomedical sciences accounted for USD 20.8 billion, up USD 1.3 billion from 2023. Together, these fields represented 50% of total higher education R&D spending. The growth in academic medical center research and life sciences funding supports a greater generation of real-world data, observational studies, and clinical research outputs, thereby increasing demand for advanced RWE analytics and evidence-generation platforms.
Moreover, the shift from volume-based to value-based care is anticipated to fuel market growth. The rising geriatric population and the increasing prevalence of chronic diseases further drive market expansion. In addition, the region’s strong market position is supported by the presence of key industry players across the U.S. and Canada. Favorable government regulations and the growing number of RWE service providers in the region are expected to further accelerate market growth.
This report forecasts revenue growth at the regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the North America real world evidence solutionsmarket report based on service, component, application, end use, therapeutic area, and region:
This product will be delivered within 1-3 business days.
The North America Real-World Evidence (RWE) solutions industry is growing, driven by strong regulatory support for the adoption of RWE solutions and expanding investments in biomedical and translational research. For instance, according to the National Center for Science and Engineering Statistics, in 2024, R&D expenditures in health sciences reached USD 38.5 billion, up USD 2.8 billion from 2023, while biological and biomedical sciences accounted for USD 20.8 billion, up USD 1.3 billion from 2023. Together, these fields represented 50% of total higher education R&D spending. The growth in academic medical center research and life sciences funding supports a greater generation of real-world data, observational studies, and clinical research outputs, thereby increasing demand for advanced RWE analytics and evidence-generation platforms.
Moreover, the shift from volume-based to value-based care is anticipated to fuel market growth. The rising geriatric population and the increasing prevalence of chronic diseases further drive market expansion. In addition, the region’s strong market position is supported by the presence of key industry players across the U.S. and Canada. Favorable government regulations and the growing number of RWE service providers in the region are expected to further accelerate market growth.
This report forecasts revenue growth at the regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the North America real world evidence solutionsmarket report based on service, component, application, end use, therapeutic area, and region:
Component Outlook (Revenue, USD Million, 2021-2033)
- Services
- Data Sets
- Clinical Settings Data
- Claims Data
- Pharmacy Data
- Patient-Powered Data
Application Outlook (Revenue, USD Million, 2021-2033)
- Drug Development & Approvals
- Medical Device Development & Approvals
- Reimbursement/Coverage and Regulatory Decision Making
- Post Market Safety & Adverse Events Monitoring
End Use Outlook (Revenue, USD Million, 2021-2033)
- Healthcare Companies (Pharmaceutical, Biopharmaceutical, Medical Device)
- Clinical research
- Commercial (inclusive of marketing, etc.)
- HEOR
- Others (market access, etc.)
- Healthcare Payers
- Healthcare Providers
- Others
Therapeutic Area Outlook (Revenue, USD Million, 2021-2033)
- Oncology
- Cardiology
- Neurology
- Diabetes
- Psychiatry
- Respiratory
- Other Therapeutic Areas (Immunology, Gastroenterology, etc.)
Country Outlook (Revenue, USD Million, 2021-2033)
- U.S.
- Canada
- Mexico
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Market Variables, Trends, & Scope
Chapter 4. North America Real World Evidence Solutions Market: Component Estimates & Trend Analysis
Chapter 5. North America Real World Evidence Solutions Market: Application Estimates & Trend Analysis
Chapter 6. North America Real World Evidence Solutions Market: End Use Estimates & Trend Analysis -
Chapter 7. North America Real World Evidence Solutions Market: Therapeutic Area Estimates & Trend Analysis
Chapter 8. North America Real World Evidence Solutions Market: Country Estimates & Trend Analysis
Chapter 9. Competitive Landscape
List of Table
List of Figures
Companies Mentioned
- Oracle
- Merative (formerly IBM Watson Health, acquired by Francisco Partners in June 2022)
- IQVIA
- ICON, plc
- Syneos Health
- Cegedim Health Data is (a division of Cegedim Group)
- Medpace
- Optum Inc. (UnitedHealth Group)
- SAS Institute Inc.
- Aetion, Inc. (acquired by Datavant in May 2025)
- Flatiron Health
- Cytel Inc.
- Trinity
- Thermo Fisher Scientific Inc.
- Parexel International Corporation
- NTT DATA, Inc.(a part of the NTT Group)
- Cognizant
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | March 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 1.34 Billion |
| Forecasted Market Value ( USD | $ 2.52 Billion |
| Compound Annual Growth Rate | 8.2% |
| Regions Covered | Global, North America |
| No. of Companies Mentioned | 17 |
